EP08.02-155 The Difference in Clinical Outcomes Between Osimertinib and EGFR-TKI plus Anti-angiogenic Agent in EGFR-mutant NSCLC Patients.

Details

Language :

English

ISSN :

15560864

Volume :

17

Issue :

9

Database :

Complementary Index

Journal :

Journal of Thoracic Oncology

Publication Type :

Academic Journal

Accession number :

159038084

Full Text :

https://doi.org/10.1016/j.jtho.2022.07.838